Artivion (AORT) Expected to Post Earnings on Thursday

Artivion (NYSE:AORT) is expected to be announcing its Q2 2026 results after the market closes on Thursday, August 6th. Analysts expect the company to post earnings of $0.0088 per share and revenue of $120.0170 million for the quarter. Investors are encouraged to explore the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Thursday, August 6, 2026 at 4:30 PM ET.

Artivion Stock Up 2.7%

Shares of Artivion stock opened at $27.54 on Tuesday. Artivion has a 52-week low of $19.16 and a 52-week high of $48.25. The company has a debt-to-equity ratio of 0.48, a quick ratio of 2.80 and a current ratio of 3.86. The business’s 50 day simple moving average is $23.20 and its 200 day simple moving average is $31.51. The firm has a market cap of $1.34 billion, a PE ratio of 114.76 and a beta of 1.24.

Analyst Ratings Changes

Several brokerages recently commented on AORT. Stifel Nicolaus set a $45.00 target price on shares of Artivion in a report on Monday, June 1st. Citizens Jmp lowered their price target on Artivion from $53.00 to $48.00 and set a “market outperform” rating on the stock in a research report on Friday, May 8th. LADENBURG THALM/SH SH upgraded Artivion from a “neutral” rating to a “buy” rating and set a $42.00 price objective on the stock in a research note on Friday, April 10th. Canaccord Genuity Group reissued a “buy” rating and issued a $36.00 price objective on shares of Artivion in a report on Tuesday, June 16th. Finally, Weiss Ratings cut shares of Artivion from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Monday, June 8th. Seven investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Artivion currently has a consensus rating of “Moderate Buy” and a consensus target price of $44.17.

Insider Transactions at Artivion

In other news, SVP Andrew M. Green sold 44,001 shares of the firm’s stock in a transaction that occurred on Thursday, June 11th. The stock was sold at an average price of $20.70, for a total value of $910,820.70. Following the completion of the sale, the senior vice president directly owned 60,259 shares of the company’s stock, valued at $1,247,361.30. This trade represents a 42.20% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 6.30% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Artivion

Several hedge funds have recently added to or reduced their stakes in the business. Caitong International Asset Management Co. Ltd bought a new position in Artivion during the third quarter worth $27,000. Smartleaf Asset Management LLC raised its position in shares of Artivion by 47.7% in the second quarter. Smartleaf Asset Management LLC now owns 1,667 shares of the company’s stock valued at $52,000 after purchasing an additional 538 shares during the period. Kemnay Advisory Services Inc. acquired a new stake in shares of Artivion during the 4th quarter worth about $79,000. Quadrant Capital Group LLC acquired a new stake in shares of Artivion during the 3rd quarter worth about $92,000. Finally, iSAM Funds UK Ltd bought a new stake in shares of Artivion during the 3rd quarter worth about $131,000. Institutional investors and hedge funds own 86.37% of the company’s stock.

About Artivion

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.